Description
Pertuzumab is the first monoclonal antibody called “HER dimerization inhibitor”. It mainly used to treat HER2-positive breast cancer. It was developed by Genentech, a subsidiary of Roche Pharma (Schweiz) AG, and was first approved in 2012. Pertuzumab entered the Chinese market in 2019. As of the first half of 2021, Roche Pharma (Schweiz) AG is the only manufacturer in the Chinese Pertuzumab market.
According to CRI’s market research, since Pertuzumab entered the Chinese market, the sales grew rapidly, from CNY21.15 million in 2019 to CNY501.69 million in 2020. The annual growth rate of Pertuzumab’s sales is 2272.15%.
CRI expects that based on the price reduction of Pertuzumab, its sales volume will continue to grow from 2021 to 2025. Pertuzumab was included in the medical insurance reimbursement catalog at the beginning of 2020, and the price of each 0.42g dose reduced from CNY18,800 to CNY4955. This price is valid until the end of 2021. The price of Pertuzumab is expected to be lowered again in the future. The price reduction will reduce the burden on patients, thereby increasing the usage rate of Pertuzumab and its sales. At the same time, the huge patient population will also enable the Pertuzumab market to continue to expand. Breast cancer is one of the top ten new cancer cases in China in 2020, reaching 420,000. Among them, HER2-positive patients accounted for 20%-30%. A large number of patients has also increased the demand for Pertuzumab. In addition, the effectiveness of the combination therapy of Pertuzumab and Trastuzumab has also laid down its potential in the market.
Topics Covered:
-The impact of COVID-19 on China’s Pertuzumab market
– Sales value of China’s Pertuzumab 2016-2020
– Competitive landscape of China’s Pertuzumab market
– Prices of Pertuzumab in China
– Prices of Pertuzumab in China by regions and manufacturers
– Analysis of factors affecting the development of China’s Pertuzumab market
– Prospect of China’s Pertuzumab market from 2021 to 2025
Table of Contents
1 Relevant Concepts of Pertuzumab
1.1 Indications for Pertuzumab
1.2 Development of Pertuzumab in China
1.3 Governmental Approval of Pertuzumab in China
1.4 The Impact of COVID-19 on Pertuzumab sales in China
2 Sales of Pertuzumab in China, 2019-2020
2.1 Sales Value of Pertuzumab
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume of Pertuzumab
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Pertuzumab by Dosage Form in China, 2019-2020
2.3.1 Injection
2.3.2 Analysis of Other Dosage Forms
3 Analysis of Major Pertuzumab Manufacturers in China, 2019-2020
3.1 Analysis of Market Share of Major Pertuzumab Manufacturers
3.1.1 Investigation on Market Share by Sales Value
3.1.2 Investigation on Market Share by Sales volume
3.2 Roche Pharma (Schweiz) AG
3.2.1 Enterprise Profile
3.2.2 Sales of PERJETA (Roche Pharma (Schweiz) AG’s Pertuzumab) in China
4 Prices of Pertuzumab for Different Manufacturers in China, 2020-2021
4.1 Roche Pharma (Schweiz) AG (PERJETA)
4.2 Analysis of Other Enterprises
5 Prospect of Chinese Pertuzumab drug Market, 2021-2025
5.1 Influential Factors of Chinese Pertuzumab Market Development
5.1.1 The Impact of COVID-19 on Chinese Pertuzumab Market
5.1.2 Market Drivers and Opportunities
5.1.3 Market Threats and Challenges
5.2 Forecast on Market Size
5.3 Forecast on Market Trend
List of Charts
Chart Patent Information About Pertuzumab Injection Registration in China
Chart Sales Value of Pertuzumab Injection over the World
Chart Sales Value of Pertuzumab Injection in China, 2019-2020
Chart Sales Value of Pertuzumab Injection in China by Region, 2019-2020
Chart Sales Volume of Pertuzumab Injection in China, 2019-2020
Chart Sales Volume of Pertuzumab Injection in China by Region, 2019-2020
Chart Market Share by Sales Value of Top Pertuzumab Manufacturers in China, 2019-2020
Chart Sales Value and Volume of PERJETA in China, 2019-2020
Chart Referential Prices of PERJETA in China, 2020-2021
Chart Forecast on Sales Value of Pertuzumab in China, 2021-2025
Chart Forecast on Sales Volume of Pertuzumab in China, 2021-2025
